Physician profile
Jamie Borgmann
NPI 1184750770
$6,350.63
in general payments reported to CMS, 2019-2025
41 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $471 · 2021: $1,182 · 2022: $645 · 2023: $998 · 2024: $1,052 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.03 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,198.36 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $650.64 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $547.75 | 2019-2025 | |
| Amgen INC. | $489.80 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $407.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $347.49 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $298.01 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.11 | 2019-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $183.75 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $181.11 | 2020-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $178.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $165.45 | 2020-2023 | Belsomra, Steglatro, Verquvo |
| Astellas Pharma US INC | $159.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $140.06 | 2019-2024 | |
| Eisai INC. | $126.09 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Borgmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.